Dual mobility implant for Hip Dysplasia

Phase-Based Progress Estimates
Hip Dysplasia+1 More
Dual mobility implant - Device
All Sexes
What conditions do you have?

Study Summary

This trial will compare two types of hip replacements to see which is better for patients at high risk for dislocation.

Eligible Conditions
  • Hip Dysplasia

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 10 years following their index surgical procedure.

Year 10
Radiographic signs of loosening and proper component placement.
Year 10

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Single bearing, traditional hip implant
1 of 2
Dual mobility
1 of 2

Active Control

Experimental Treatment

412 Total Participants · 2 Treatment Groups

Primary Treatment: Dual mobility implant · No Placebo Group · Phase 4

Dual mobility
Experimental Group · 1 Intervention: Dual mobility implant · Intervention Types: Device
Single bearing, traditional hip implant
ActiveComparator Group · 1 Intervention: Traditional, Single-bearing hip implant · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 10 years following their index surgical procedure.

Who is running the clinical trial?

Keck School of Medicine of USCUNKNOWN
2 Previous Clinical Trials
48 Total Patients Enrolled
New York UniversityOTHER
199 Previous Clinical Trials
300,529 Total Patients Enrolled
Rush University Medical CenterLead Sponsor
381 Previous Clinical Trials
150,753 Total Patients Enrolled
Rothman Institute OrthopaedicsOTHER
112 Previous Clinical Trials
19,701 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 3rd, 2021

Last Reviewed: November 15th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.